Bilibili revenue climbs to RMB7.94 billion
Bilibili (NASDAQ:BILI) reported second quarter 2026 total net revenues of RMB7.94 billion, up 8% year over year, as advertising revenue increased 28% to RMB3.13 billion.
Bilibili (NASDAQ:BILI) reported second quarter 2026 total net revenues of RMB7.94 billion, up 8% year over year, as advertising revenue increased 28% to RMB3.13 billion.
Lotus Technology (NASDAQ:LOT) reported first half 2026 revenue of $268 million, up 23% year over year, as vehicle deliveries increased 39% to 3,904 units following the launch of the PHEV model Eletre X.
Canadian Solar (NASDAQ:CSIQ) reported second quarter 2026 net revenue of $1.2 billion, up 12% from the previous quarter but down 29% year over year, while battery energy storage shipments increased to 3.7 GWh.
Brent crude futures fell $1.36, or 1.55%, to $86.48 a barrel, while West Texas Intermediate (WTI) crude futures declined $1.40, or 1.7%, to $80.83 as markets reacted to expectations of reduced supply disruptions.
Standard Nuclear (NYSE:STDN) reported second quarter 2026 revenue of $4.7 million, up from $0.6 million in the prior-year period, while total contract backlog later increased to $576.9 million following new customer agreements.
Marvell Technology (NASDAQ:MRVL) reported record fiscal 2027 second-quarter net revenue of $2.739 billion, up 37% year over year and $39 million above the midpoint of its previous guidance.
Mesoblast (NASDAQ:MESO) reported FY2026 total revenue of $120.3 million, up from $17.2 million a year earlier, as the company recorded its first full U.S. commercial year of Ryoncil sales.
Materialise NV (NASDAQ:MTLS) reported second quarter 2026 revenue of EUR70.1 million, up 8.1% year over year, while adjusted EBITDA increased to EUR9.6 million from EUR8.3 million.
CMB.TECH (NYSE:CMBT) reported unaudited second quarter 2026 revenue of USD703.9 million, compared with USD387.8 million in the same period last year, while profit for the period reached USD364.4 million.
AbbVie (NYSE:ABBV) submitted a regulatory application to the European Medicines Agency for subcutaneous SKYRIZI (risankizumab) induction treatment in adults with moderately to severely active Crohn’s disease.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy